|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
Globocan estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Erdei E and Torres SM: A new understanding
in the epidemiology of melanoma. Expert Rev Anticancer Ther.
10:1811–1823. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guy GP Jr, Thomas CC, Thompson T, Watson
M, Massetti GM and Richardson LC; Centers for Disease Control and
Prevention (CDC): Vital signs: Melanoma incidence and mortality
trends and projections-United States, 1982-2030. MMWR Morb Mortal
Wkly Rep. 64:591–596. 2015.PubMed/NCBI
|
|
4
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rigel DS and Carucci JA: Malignant
melanoma: Prevention, early detection, and treatment in the 21st
century. CA Cancer J Clin. 50:215–240; quiz 237-240. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park BR, Park JW, Cho CK, Yoo HS and Lee
YW: A case of breast cancer patient experiencing adriamycin cytoxan
and taxol side effects managed by traditional korean medicine. J
Int Korean Med. 32:451–457. 2011.
|
|
8
|
Zhang QY, Wang FX, Jia KK and Kong LD:
Natural product interventions for chemotherapy and
radiotherapy-induced side effects. Front Pharmacol. 9:12532018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olofinsan K, Abrahamse H and George BP:
Therapeutic role of alkaloids and alkaloid derivatives in cancer
management. Molecules. 28:55782023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye H, Wang L, Ma L, Ionov M, Qiao G, Huang
J, Cheng L, Zhang Y, Yang X, Cao S and Lin X: Protein kinases as
therapeutic targets to develop anticancer drugs with natural
alkaloids. Front Biosci (Landmark Ed). 26:1349–1361. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Piska K, Gunia-Krzyżak A, Koczurkiewicz P,
Wójcik-Pszczoła K and Pękala E: Piperlongumine (piplartine) as a
lead compound for anticancer agents-synthesis and properties of
analogues: A mini-review. Eur J Med Chem. 156:13–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parama D, Rana V, Girisa S, Verma E,
Daimary UD, Thakur KK, Kumar A and Kunnumakkara AB: The promising
potential of piperlongumine as an emerging therapeutics for cancer.
Explor Target Antitumor Ther. 2:323–354. 2021.PubMed/NCBI
|
|
13
|
Tripathi SK and Biswal BK: Piperlongumine,
a potent anticancer phytotherapeutic: Perspectives on contemporary
status and future possibilities as an anticancer agent. Pharmacol
Res. 156:1047722020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu P, Qian J, Xu Z, Meng C, Zhu W, Ran F,
Zhang W, Zhang Y and Ling Y: Overview of piperlongumine analogues
and their therapeutic potential. Eur J Med Chem. 220:1134712021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar S and Agnihotri N: Piperlongumine
targets NF-κB and its downstream signaling pathways to suppress
tumor growth and metastatic potential in experimental colon cancer.
Mol Cell Biochem. 476:1765–1781. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang F, Mao Y, You Q, Hua D and Cai D:
Piperlongumine induces apoptosis and autophagy in human lung cancer
cells through inhibition of PI3K/AKT/mTOR pathway. Int J
Immunopathol Pharmacol. 28:362–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song B, Zhan H, Bian Q and Gu J:
Piperlongumine inhibits gastric cancer cells via suppression of the
JAK1,2/STAT3 signaling pathway. Mol Med Rep. 13:4475–4480. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Golovine KV, Makhov PB, Teper E, Kutikov
A, Canter D, Uzzo RG and Kolenko VM: Piperlongumine induces rapid
depletion of the androgen receptor in human prostate cancer cells.
Prostate. 73:23–30. 2013. View Article : Google Scholar
|
|
19
|
Dhillon H, Chikara S and Reindl KM:
Piperlongumine induces pancreatic cancer cell death by enhancing
reactive oxygen species and DNA damage. Toxicol Rep. 1:309–318.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kerr JF: History of the events leading to
the formulation of the apoptosis concept. Toxicology.
181-182:471–474. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu X, Lai Y and Hua ZC: Apoptosis and
apoptotic body: Disease message and therapeutic target potentials.
Biosci Rep. 39:BSR201809922019. View Article : Google Scholar :
|
|
22
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hongmei Z: Extrinsic and intrinsic
apoptosis signal pathway review. Apoptosis and Medicine. InTech.
2012. View Article : Google Scholar
|
|
24
|
Mullen P: PARP cleavage as a means of
assessing apoptosis. Methods Mol Med. 88:171–181. 2004.
|
|
25
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue J and López JM: Understanding MAPK
signaling pathways in apoptosis. Int J Mol Sci. 21:23462020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanida I, Ueno T and Kominami E: LC3 and
autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paquette M, El-Houjeiri L and Pause A:
mTOR pathways in cancer and autophagy. Cancers (Basel). 10:182018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Janku F, McConkey DJ, Hong DS and Kurzrock
R: Autophagy as a target for anticancer therapy. Nat Rev Clin
Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sriramarao P and Bourdon MA: Melanoma cell
invasive and metastatic potential correlates with endothelial cell
reorganization and tenascin expression. Endothelium. 4:85–97. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hazarika P, McCarty MF, Prieto VG, George
S, Babu D, Koul D, Bar-Eli M and Duvic M: Up-regulation of
Flotillin-2 is associated with melanoma progression and modulates
expression of the thrombin receptor protease activated receptor 1.
Cancer Res. 64:7361–7369. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xi G, Hu X, Wu B, Jiang H, Young CY, Pang
Y and Yuan H: Autophagy inhibition promotes paclitaxel-induced
apoptosis in cancer cells. Cancer Letters. 307:141–148. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Taatjes DJ, Sobel BE and Budd RC:
Morphological and cytochemical determination of cell death by
apoptosis. Histochem Cell Biol. 129:33–43. 2008. View Article : Google Scholar
|
|
35
|
Rawat L, Hegde H, Hoti SL and Nayak V:
Piperlongumine induces ROS mediated cell death and synergizes
paclitaxel in human intestinal cancer cells. Biomed Pharmacother.
128:1102432020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin TH, Kuo CH, Zhang YS, Chen PT, Chen
SH, Li YZ and Lee YR: Piperlongumine induces cellular apoptosis and
autophagy via the ROS/AKT signaling pathway in human follicular
thyroid cancer cells. Int J Mol Sci. 24:80482023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Afolabi LO, Bi J, Chen L and Wan X: A
natural product, Piperlongumine (PL), increases tumor cells
sensitivity to NK cell killing. Int Immunopharmacol. 96:1076582021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi DG, Venkatesan J and Shim MS:
Selective anticancer therapy using pro-oxidant drug-loaded
chitosan-fucoidan nanoparticles. Int J Mol Sci. 20:32202019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Atale N, Gupta S, Yadav UC and Rani V:
Cell-death assessment by fluorescent and nonfluorescent cytosolic
and nuclear staining techniques. J Micros. 255:7–19. 2014.
View Article : Google Scholar
|
|
40
|
Zheng J, Son DJ, Gu SM, Woo JR, Ham YW,
Lee HP, Kim WJ, Jung JK and Hong JT: Piperlongumine inhibits lung
tumor growth via inhibition of nuclear factor kappa B signaling
pathway. Sci Rep. 6:263572016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang DF, Yang ZC, Chen JQ, Jin XX, Qiu
YD, Chen XJ, Shi HY, Liu ZG, Wang MS, Liang G and Zheng XH:
Piperlongumine inhibits migration and proliferation of
castration-resistant prostate cancer cells via triggering
persistent DNA damage. BMC Complementary Med Ther. 21:1–15.
2021.
|
|
42
|
Scott WL and Athena WL: Apoptosis in
cancer. Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar
|
|
43
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and
Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med.
19:1997–2007. 2023.
|
|
44
|
Chen SY, Huang HY, Lin HP and Fang CY:
Piperlongumine induces autophagy in biliary cancer cells via
reactive oxygen species-activated ERK signaling pathway. Int J Mol
Med. 44:1687–1696. 2019.PubMed/NCBI
|
|
45
|
Lee JH, Han SH, Kim YM, Kim SH, Yoo ES,
Woo JS, Jung GH, Jung SH, Kim BS and Jung JY: Shikonin inhibits
proliferation of melanoma cells by MAPK pathway-mediated induction
of apoptosis. Biosci Rep. 41:BSR202038342023. View Article : Google Scholar
|
|
46
|
Lee CW, Yen FL, Ko HH, Li SY, Chiang YC,
Lee MH, Tsai MH and Hsu LF: Cudraflavone C induces apoptosis of
A375.S2 melanoma cells through mitochondrial ROS production and
MAPK activation. Int J Mol Sci. 18:15082017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Paglin S, Hollister T, Delohery T, Hackett
N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response
of cancer cells to radiation involves autophagy and formation of
acidic vesicles. Cancer Res. 61:439–444. 2023.
|
|
48
|
Fukuda T, Oda K, Wada-Hiraike O, Sone K,
Inaba K, Ikeda Y, Makii C, Miyasaka A, Kashiyama T, Tanikawa M, et
al: Autophagy inhibition augments resveratrol-induced apoptosis in
ishikawa endometrial cancer cells. Oncol Lett. 12:2560–2566. 2023.
View Article : Google Scholar
|
|
49
|
Randhawa H, Kibble K, Zeng H, Moyer MP and
Reindl KM: Activation of ERK signaling and induction of colon
cancer cell death by piperlongumine. Toxicol In Vitro.
27:1626–1633. 2013. View Article : Google Scholar : PubMed/NCBI
|
